Estimated overall survival according to Kaplan-Meier analysis was 67.5 % ( 95 % CI 61.0 % -73.1 % ) in the placebo group and 69.4 % ( 95 % CI 63.0 % -74.9 % ) in the olesoxime group ; hence survival was not significantly different between treatment arms ( P = 0.71 , stratified bulbar/spinal log-rank ) .